Search Results
| نشرة الممارس الصحي | نشرة معلومات المريض بالعربية | نشرة معلومات المريض بالانجليزية | صور الدواء | بيانات الدواء |
|---|
DESCRIPTION
Antihemophilic Factor (Human), Ko¯atew-DVI, is a sterile, stable, purified, dried concentrate of human Antihemophilic Factor (AHF, Factor VIII) which has been treated with tri-n-butyl phosphate (TNBP) and polysorbate 80 and heated in lyophilized form in the final container at 80°C for 72 hours. Koa¯te-DVI is intended for use in therapy of classical hemophilia (hemophilia A).
Koa¯te-DVI is purified from the cold insoluble fraction of pooled fresh-frozen plasma by modification and refinements of the methods first described by Hershgold, Pool, and Pappenhagen.(1) Koa¯te-DVI contains purified and concentrated Factor VIII. The Factor VIII is 300–1000 times purified over whole plasma. Part of the fractionation may be performed by another licensed manufacturer. When reconstituted as directed, Koa¯te-DVI contains approximately 50–150 times as much Factor VIII as an equal volume of fresh plasma. The specific activity, after addition of Albumin (Human), is in the range of 9–22 IU/mg protein. Koa¯te-DVI must be administered by the intravenous route.
Each bottle of Koa¯te-DVI contains the labeled amount of antihemophilic factor activity in international units (IU). One IU, as defined by the World Health Organization standard for blood coagulation Factor VIII, human, is approximately equal to the level of Factor VIII found in 1.0 mL of fresh pooled human plasma. The final product when reconstituted as directed contains not more than (NMT) 1500 µg/mL polyethylene glycol (PEG), NMT 0.05 M glycine, NMT 25 µg/mL polysorbate 80, NMT 5 µg/g tri-n-butyl phosphate (TNBP), NMT 3 mM calcium, NMT 1 µg/mL aluminum, NMT 0.06 M histidine, and NMT 10 mg/mL Albumin (Human).
CLINICAL PHARMACOLOGY
Hemophilia A is a hereditary bleeding disorder characterized by deficient coagulant activity of the specific plasma protein clotting factor, Factor VIII. In afflicted individuals, hemorrhages may occur spontaneously or after only minor trauma. Surgery on such individuals is not feasible without first correcting the clotting abnormality. The administration of Koa¯te-DVI provides an increase in plasma levels of Factor VIII and can temporarily correct the coagulation defect in these patients.
After infusion of Antihemophilic Factor (Human), there is usually an instantaneous rise in the coagulant level followed by an initial rapid decrease in activity, and then a subsequent much slower rate of decrease in activity.(2-4) The early rapid phase may represent the time of equilibration with the extravascular compartment, and the second or slow phase of the survival curve presumably is the result of degradation and reflects the true biologic half-life of the infused Antihemophilic Factor (Human).(3)
The removal and inactivation of spiked relevant and model enveloped and non-enveloped viruses during the manufacturing process for Koa¯te-DVI have been validated in laboratory studies at Grifols Therapeutics Inc. Studies performed with the model enveloped viruses indicated that the greatest reduction was achieved by TNBP/polysorbate 80 treatment and 80°C heat. For this reason, VSV (Vesicular Stomatitis Virus, model for RNA enveloped viruses) and HIV-1 (Human Immunodeficiency Virus Type 1) were studied only at these two steps of the manufacturing process. The efficacy of the dry heat treatment was studied using all of the viruses, including BVDV (Bovine Viral Diarrheal Virus, model for hepatitis C virus) and Reo (Reovirus Type 3, model for viruses resistant to physical and chemical agents, such as hepatitis A), and the effect of moisture content on the inactivation of HAV (Hepatitis A Virus), PPV (Porcine Parvovirus, model for parvovirus B19), and PRV (Pseudorabies Virus, model for large enveloped DNA viruses) was investigated.
Similar studies have shown that a terminal 80°C heat incubation for 72 hours inactivates non-lipid enveloped viruses such as hepatitis A and canine parvovirus in vitro, as well as lipid enveloped viruses such as hepatitis C.(5-7)
Koa¯te-DVI is purified by a gel permeation chromatography step serving the dual purpose of reducing the amount of TNBP and polysorbate 80 as well as increasing the purity of the Factor VIII.
A two-stage clinical study using Koa¯te-DVI was performed in individuals with hemophilia A who had been previously treated with other plasma-derived Factor VIII concentrates. In Stage 1 of the pharmacokinetic study with 19 individuals, statistical comparisons demonstrated that Koa¯te-DVI is bioequivalent to the unheated product, Ko¯atew-HP. The incremental in vivo recovery ten minutes after infusion of Koa¯te-DVI was 1.90% IU/kg (Koa¯te-HP 1.82% IU/kg). Mean biologic half-life of Koa¯te-DVI was 16.12 hours (Koa¯te-HP 16.13 hours). In Stage II of the study, participants received Koa¯te-DVI treatments for six months on home therapy with a median of 52 days (range 23–94). No evidence of inhibitor formation was observed, either in the clinical study or in the preclinical investigations.(2)
DOSAGE AND ADMINISTRATION
Each bottle of Koa¯te-DVI has the Factor VIII content in international units (IU) per bottle stated on the label of the bottle. The reconstituted product must be administered intravenously by either direct syringe injection or drip infusion. The product must be administered within 3 hours after reconsti-tution.
General Approach to Treatment and Assessment of Treatment Efficacy
The dosages described below are presented as general guidance. It should be emphasized that the dosage of Koa¯te-DVI required for hemostasis must be individualized according to the needs of the patient, the severity of the deficiency, the severity of the hemorrhage, the presence of inhibitors, and the Factor VIII level desired. It is often critical to follow the course of therapy with Factor VIII level assays.
The clinical effect of Koa¯te-DVI is the most important element in evaluating the effectiveness of treatment. It may be necessary to administer more Koa¯te-DVI than would be estimated in order to attain satisfactory clinical results. If the calculated dose fails to attain the expected Factor VIII levels, or if bleeding is not controlled after administration of the calculated dosage, the presence of a circulating inhibitor in the patient should be suspected. Its presence should be substantiated and the inhibitor level quantitated by appropriate laboratory tests.
When an inhibitor is present, the dosage requirement for Antihemophilic Factor (Human) is extremely variable and the dosage can be determined only by the clinical response. Some patients with low titer inhibitors (10 Bethesda Units) can be successfully treated with Factor VIII without a resultant anamnestic rise in inhibitor titer.(12) Factor VIII levels and clinical response to treatment must be assessed to insure adequate response. Use of alternative treatment products, such as Factor IX Complex concentrates, Antihemophilic Factor (Porcine) or Anti-Inhibitor Coagulant Complex,
may be necessary for patients with high titer inhibitors. Immune tolerance therapy using repeated doses of Factor VIII concentrate administered frequently on a predetermined schedule may result in eradication of the Factor VIII inhibitor.(13,14) Most successful regimens have employed high doses of Factor VIII administered at least once daily, but no single dosage regimen has been universally accepted as the most effective. Consultation with a hemophilia expert experienced with the management of immune tolerance regimens is also advisable.
DOSAGE AND ADMINISTRATION
Each bottle of Koa¯te-DVI has the Factor VIII content in international units (IU) per bottle stated on the label of the bottle. The reconstituted product must be administered intravenously by either direct syringe injection or drip infusion. The product must be administered within 3 hours after reconsti-tution.
General Approach to Treatment and Assessment of Treatment Efficacy
The dosages described below are presented as general guidance. It should be emphasized that the dosage of Koa¯te-DVI required for hemostasis must be individualized according to the needs of the patient, the severity of the deficiency, the severity of the hemorrhage, the presence of inhibitors, and the Factor VIII level desired. It is often critical to follow the course of therapy with Factor VIII level assays.
The clinical effect of Koa¯te-DVI is the most important element in evaluating the effectiveness of treatment. It may be necessary to administer more Koa¯te-DVI than would be estimated in order to attain satisfactory clinical results. If the calculated dose fails to attain the expected Factor VIII levels, or if bleeding is not controlled after administration of the calculated dosage, the presence of a circulating inhibitor in the patient should be suspected. Its presence should be substantiated and the inhibitor level quantitated by appropriate laboratory tests.
When an inhibitor is present, the dosage requirement for Antihemophilic Factor (Human) is extremely variable and the dosage can be determined only by the clinical response. Some patients with low titer inhibitors (10 Bethesda Units) can be successfully treated with Factor VIII without a resultant anamnestic rise in inhibitor titer.(12) Factor VIII levels and clinical response to treatment must be assessed to insure adequate response. Use of alternative treatment products, such as Factor IX Complex concentrates, Antihemophilic Factor (Porcine) or Anti-Inhibitor Coagulant Complex,
may be necessary for patients with high titer inhibitors. Immune tolerance therapy using repeated doses of Factor VIII concentrate administered frequently on a predetermined schedule may result in eradication of the Factor VIII inhibitor.(13,14) Most successful regimens have employed high doses of Factor VIII administered at least once daily, but no single dosage regimen has been universally accepted as the most effective. Consultation with a hemophilia expert experienced with the management of immune tolerance regimens is also advisable.
Rate of Administration
The rate of administration should be adapted to the response of the individual patient, but administration of the entire dose in 5 to 10 minutes is generally well-tolerated.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
ADVERSE REACTIONS
Allergic-type reactions may result from the administration of Antihemophilic Factor (Human) preparations.(10,11)
Ten adverse reactions related to 7 infusions were observed during a total of 1053 infusions performed during the clinical study of Koa¯te-DVI, for a frequency of 0.7% infusions associated with adverse reactions. All reactions were mild and included paraesthesia, vision blurred, headache, nausea, abdominal pain, and feeling jittery.(2)
STORAGE
Koa¯te-DVI should be stored under refrigeration (2–8°C; 36–46°F). Storage of lyophilized powder at room temperature (up to 25°C or 77°F) for 6 months, such as in home treatment situations, may be done without loss of Factor VIII activity. Freezing should be avoided as breakage of the diluent bottle might occur.
Koa¯te-DVI is supplied in a kit containing one single use vial of Koa¯te-DVI lyophilized powder, one vial of Sterile Water for Injection, USP, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set. The total activity of Factor VIII in International Units is stated on the label of the Koa¯te-DVI vial.
Grifols Therapeutics Inc.
Research Triangle Park, NC 27709 USA
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
النشرة غير مترجمة للعربية حاليا لأن المستحضر للمستشفيات فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
Koāte-DVI is indicated:
• for the control and prevention of bleeding episodes, or
• in order to perform emergency and elective surgery in patients with hemophilia A (hereditary Factor VIII deficiency).
Koāte-DVI is not indicated for the treatment of von Willebrand disease.
For intravenous use after reconstitution only.
Posology
• Dose and duration of treatment depend on the severity of the Factor VIII deficiency,
location and extent of bleeding, and the patient’s clinical condition.
• Each vial of Koāte-DVI is labeled with the actual Factor VIII potency in international units (IU). Calculation of the required dose of Factor VIII is based on the empirical
finding that one IU of Factor VIII per kg body weight raises the plasma Factor VIII activity by approximately 2% of normal activity or 2 IU/dL.
• The required dose can be determined using the following formula:
Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5
• Estimate the expected in vivo peak increase in Factor VIII level, expressed as IU/dL (or
% normal), using the following formula:
Estimated Increment of Factor VIII (% normal or IU/dL) = [Total Dose (IU)/Body Weight (kg)] x 2
• Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical
responses. Base the dose and frequency on the individual clinical response.
Control and Prevention of Bleeding Episodes
A guide for dosing Koāte-DVI for the control and prevention of bleeding episodes is provided in Table 1. Consideration should be given to maintaining a Factor VIII activity at or
above the target range.
It should be emphasized that the dosage of Koāte-DVI required for hemostasis must be individualized according to the needs of the patient, the severity of the deficiency, the
severity of the hemorrhage, the presence of inhibitors, and the Factor VIII level desired. It is often critical to follow the course of therapy with Factor VIII level assays.
The clinical effect of Koāte-DVI is the most important element in evaluating the effectiveness of treatment.
It may be necessary to administer more Koāte-DVI than would be estimated in order to attain satisfactory clinical results. If the calculated dose fails to attain
the expected Factor VIII levels, or if bleeding is not controlled after administration of the calculated dosage, the presence of a circulating inhibitor in the patient should be suspected.
Its presence should be substantiated and the inhibitor level quantitated by appropriate laboratory tests.
When an inhibitor is present, the dosage requirement for Antihemophilic Factor VIII (Human) is extremely variable and the dosage can be determined only by the clinical
response. Some patients with low titer inhibitors (10 Bethesda Units) can be successfully treated with Factor VIII without a resultant anamnestic rise in inhibitor titer. Factor VIII
levels and clinical response to treatment must be assessed to insure adequate response. Immune tolerance therapy using repeated doses of Factor VIII concentrate administered
frequently on a predetermined schedule may result in eradication of the Factor VIII inhibitor.
Most successful regimens have employed high doses of Factor VIII administered at least once daily, but no single dosage regimen has been universally accepted as the most effective.
Consultation with a hemophilia expert experienced with the management of immune tolerance regimens is also advisable.
Method of administration
For intravenous use after reconstitution only.
• If the dose requires more than one vial of Koāte-DVI:
o Reconstitute each vial using a new transfer needle.
o Draw up all the solution into a single syringe.
• Visually inspect the final solution for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter
or discoloration is observed.
• Attach the syringe to the connector end of an infusion set.
• Administer intravenously. The rate of administration should be determined by the
patient’s comfort level, and no faster than 10 mL per minute.
Elderly population
Clinical studies of Koāte-DVI did not include any subjects aged 65 and over to determine whether they respond differently from younger subjects. Individualize dose selection for
geriatric patients.
Paediatric population
Koāte-DVI has not been studied in paediatric patients. The unheated, solvent/detergent
treated Koāte had been used extensively in paediatric patients. Because clearance of Factor VIII (based on per kilogram body weight) is higher in children, higher or more frequent
dosing may be needed.
Spontaneous adverse event reports with the unheated product and Koāte-DVI for paediatric use were within the experience of those reports for adult use.
Hypersensitivity reactions
Hypersensitivity reactions, including anaphylaxis, are possible. Early signs of
hypersensitivity reactions, which can progress to anaphylaxis, may include angioedema,
chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and
dyspnea. If hypersensitivity symptoms occur, discontinue use of the product immediately
and administer appropriate emergency treatment.
Neutralizing antibodies
The formation of neutralizing antibodies (inhibitors) to Factor VIII may occur. Monitor all
patients for the development of Factor VIII inhibitors by appropriate clinical observations
and laboratory tests. If expected plasma Factor VIII activity levels are not attained, or if
bleeding is not controlled with an appropriate dose, perform an assay that measures Factor
VIII inhibitor concentration.
Intravascular hemolysis
Koāte-DVI contains blood group isoagglutinins which are not clinically significant when
small doses are used to treat minor bleeding episodes. However, when large and/or frequent
doses of Koāte-DVI are given to patients with blood groups A, B, or AB, acute hemolytic
anemia may occur, resulting in increased bleeding tendency or hyperfibrinogenemia. Monitor
these patients for signs of intravascular hemolysis and falling hematocrit. Should this
condition occur, leading to progressive hemolytic anemia, discontinue Koāte-DVI and
consider administering serologically compatible Type O red blood cells and providing
alternative therapy.
Transmissible infectious agents
Standard measures to prevent infections resulting from the use of medicinal products
prepared from human blood or plasma include selection of donors, screening of individual
donations and plasma pools for specific markers of infection and the inclusion of effective
manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal
products prepared from human blood or plasma are administered, the possibility of
transmitting infective agents cannot be totally excluded. This also applies to unknown or
emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and
HCV. The measures taken may be of limited value against non-enveloped viruses such as
HAV and parvovirus B19. Parvovirus B19 infection may be serious for pregnant women
(foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g.
haemolytic anaemia).
No interactions of Antihemophilic Factor VIII (Human) products with other medicinal
products have been reported.
Monitoring Laboratory Tests
• Monitor plasma Factor VIII activity levels by performing a validated test (e.g., one-stage
clotting assay) to confirm that adequate Factor VIII levels have been achieved and
maintained.
• Monitor for the development of Factor VIII inhibitors. Perform a Bethesda inhibitor
assay if expected Factor VIII plasma levels are not attained, or if bleeding is not
controlled with the expected dose of Koāte-DVI. Use Bethesda Units (BU) to report
inhibitor levels.
• Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A,
B or AB blood groups who are receiving large or frequent doses of Koāte-DVI.
Fertility
Effect of Koāte-DVI on reproduction and fertility is not known.
Pregnancy
Pregnancy Category C. Animal reproduction studies have not been conducted with Koāte-
DVI. It is also not known whether Koāte-DVI can cause fetal harm when administered to a
pregnant woman or can affect reproduction capacity. Koāte-DVI should be given to a
pregnant woman only if clearly needed.
Lactation
There is insufficient/limited information on the excretion of Antihemophilic Factor (Human)
in human or animal breast milk. A risk to the suckling child cannot be excluded. A decision
on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with
Koāte-DVI should be made taking into account the benefit of breast-feeding to the child and
the benefit of Koāte-DVI therapy to the woman.
No studies on the effects on the ability to drive and use machines have been performed.
Summary of the safety profile
The most common adverse drug reactions (frequency ≥ 5% of subjects) observed in the
clinical trial were nervousness, headache, abdominal pain, nausea, paresthesia and blurred
vision.
Post Marketing
Because postmarketing reporting of adverse reactions is voluntary and from a population of
uncertain size, it is not always possible to reliably estimate the frequency of these reactions
or establish a causal relationship to product exposure.
• Blood and Lymphatic System Disorders: Factor VIII inhibition, hemolytic
anemia
• Immune System Disorders: Hypersensitivity including anaphylaxis, rash, pruritus
• Injury, Poisoning and Procedural Complications: Post-procedural hemorrhage
• Nervous System Disorders: Generalized clonic-tonic seizure
Overdose symptoms with Antihemophilic Factor VIII (Human) are not known.
Pharmacotherapeutic Group: coagulation factor viii. ATC code: B02BD02
Mechanism of action
Koāte-DVI temporarily replaces the missing clotting Factor VIII that is needed for effective
hemostasis.
Pharmacodynamic effects
Hemophilia A is a bleeding disorder characterized by a deficiency of functional coagulation
Factor VIII, resulting in a prolonged plasma clotting time as measured by the activated
partial thromboplastin time (aPTT) assay. Treatment with Koāte-DVI normalizes the aPTT
over the effective dosing period.
Clinical efficacy and safety
Efficacy
The efficacy of Koāte-DVI for the treatment of bleeding episodes was demonstrated in a 2-
stage, safety, PK and efficacy clinical trial. Stage I was a randomized, single-blind, singledose,
crossover, and PK study comparing heat-treated Koāte-DVI with unheated Koāte-DVI.
Nineteen subjects were randomized and received a single dose of 50 IU/kg of either heated
Koāte-DVI or unheated Koāte-DVI for PK assessment. Stage II was a 6 month open-label
safety study conducted at two hemophilia centers. Nineteen subjects received Koāte-DVI,
including for on-demand treatment and control of bleeding episodes. The study populations
included 15 Caucasians, 3 Hispanic, and 1 Black subjects. A total of 306 bleeding episodes
were treated, of which 82% were treated with a single infusion of Factor VIII.
Safety
Because clinical studies are conducted under widely varying conditions, adverse reaction
rates observed cannot be directly compared to rates in other clinical trials and may not reflect
the rates observed in practice.
The safety assessment of Koāte-DVI is based on data from a 2-stage, safety, pharmacokinetic
(PK) and efficacy clinical trial in which twenty subjects with severe hemophilia A (<1%
endogenous Factor VIII activity) were evaluable for safety. Nineteen subjects were enrolled
in Stage I of the trial, including 15 Caucasian, 3 Hispanic, and 1 Black subjects. The mean
age was 29 years (range: 13.9 – 46.4 years). Nineteen subjects, including the 18 subjects who
completed Stage I, and one new subject were enrolled in Stage II. The mean age was 30
years (range: 13.9 – 46.4). The subjects received a total of 1053 infusions. Ten adverse
reactions related to 7 infusions were reported in 4 subjects. These were: nervousness (2
subjects [10%]), headache (1 subject [5%]), abdominal pain (1 subject [5%]), nausea (1
subject [5%]), paresthesia (1 subject [5%]), and blurred vision (1 subject [5%]).
Subjects were monitored for neutralizing antibodies (inhibitors) to Factor VIII by the
Bethesda assay at baseline and at 8, 17 and 26 weeks. No evidence of inhibitor formation was
observed in the clinical trial.
The detection of antibody formation is highly dependent on the sensitivity and specificity of
the assay. Additionally, the observed incidence of antibody (including neutralizing antibody)
positivity in an assay may be influenced by several factors including assay methodology,
sample handling, timing of sample collection, concomitant medications, and underlying
disease. For these reasons, it may be misleading to compare the incidence of antibodies to
Koāte-DVI in the study described above with the incidence of antibodies in other studies or
to other products.
The pharmacokinetics (PK) of Koāte-DVI were evaluated in a prospective, two-stage clinical
trial of 20 previously treated patients (PTPs) with severe hemophilia A. In Stage I, the PK
parameters for 19 subjects were based on plasma Factor VIII activity after a single
intravenous infusion of 50 IU/kg of Koāte-DVI. Bioequivalence of the dry heat-treated
Koāte-DVI to the unheated Koāte-DVI was demonstrated by comparison of Cmax and the area
under the curve, AUC0-48. The incremental in vivo recovery ten minutes after
infusion of dry heat-treated Koāte-DVI was 1.90% unit/kg (unheated Koāte-DVI was 1.82%
units/kg). Mean biologic half-life was 16.1 hours.
In Stage II of the study, participants received Koāte-DVI treatments for six months on home
therapy with a median of 52 days (range 23 to 94 days). At the end of 6 months, the mean
AUC0-48 was 1471 ± 237 unit*hour/100 mL, the Cmax was 99 ± 13 unit/100 mL, and the t1/2
was 16 ± 3.9 hours.
The Koāte-DVI manufacturing process includes two dedicated steps with virus inactivation capacity. The solvent/detergent treatment step has the capacity to inactivate enveloped
viruses (such as HIV, HCV, HBV, and WNV). Heat treatment at 80ºC for 72 hours has the capacity to inactivate enveloped viruses (such as HIV and HCV) as well as non-enveloped viruses (such as HAV and B19V). The polyethylene glycol (PEG) precipitation/depth filtration step has the capacity to remove both enveloped and non-enveloped viruses.
Additionally, the Koāte-DVI manufacturing process was investigated for its capacity to
decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy
(TSE), considered a model for the variant Creutzfeldt-Jakob disease (vCJD) and Creutzfeldt-
Jakob disease (CJD) agents. The manufacturing process has been shown to decrease TSE
infectivity of that experimental model agent (a total of 5.1 log10 reduction), providing
reasonable assurance that low levels of vCJD/CJD agent infectivity, if present in the starting
material, would be removed.
Sodium Chloride
Calcium Chloride
L-Histidine
Human Albumin
Solvent: Water for Injection
Antihemophilic Factor VIII (Human) should not be mixed with other medicinal products.
Only the provided infusion set should be used because treatment failure can occur as a
consequence of Antihemophilic Factor VIII (Human) adsorption to the internal surfaces of
some infusion equipment.
• Store Koāte-DVI in its original package to protect it from light.
• Store the Koāte-DVI package at 2 to 8°C (36 to 46°F). Do not freeze.
• Koāte-DVI may also be stored at room temperature (up to 25°C or 77°F) for up to 6 months.
• Do not use after the expiration date.
• Use Koāte-DVI immediately or within 3 hours of reconstitution. Do not refrigerate the reconstituted solution
Koāte-DVI is supplied in a 10 mL clear type I glass vial closed with chlorobutyl stopper,
protected with an aluminum flip-off cap. The vial contains 500 IU Antihemophilic Factor
VIII (Human).
Sterile Water for Injection, USP, is supplied in a type I glass vial closed with butyl rubber
stopper, protected with an aluminum flip-off cap. The diluent vial contains 5 mL sterile
water for injection.
Koāte-DVI is supplied in a kit containing one single use vial of Koāte-DVI lyophilized
powder, one vial of Sterile Water for Injection, USP, one sterile double-ended transfer
needle, one sterile filter needle, and one sterile administration set. The total activity of Factor
VIII in International Units is stated on the label of the Koāte-DVI vial and carton.
Components of the packaging do not contain natural rubber latex.
1. Use aseptic technique (clean and sanitized) and a flat work surface during the
reconstitution procedure.
2. Bring the vials of Koāte-DVI and the diluent (Sterile Water for Injection) to room
temperature before use.
3. Remove the shrink band from Koāte-DVI vial. Do not use Koāte-DVI if the shrink band
is absent or shows signs of tampering, and notify Grifols Therapeutics Inc. immediately.
4. Remove the plastic cap from the Koāte-DVI vial and cleanthe top of the stopper
with an alcohol swab. Allow the stopper to dry.
5. Repeat this step with the vial of sterile water.
6. Carefully remove the plastic sheath from the short end of the transfer needle and insert
the exposed needle into the diluent vial to the hub.
7. Place the Koāte-DVI vial upright on a flat surface. Remove the sheath from the other end
of the transfer needle.
8. While holding the Koāte-DVI vial securely on a flat surface insert the needle into the vial
at a 45° angle to minimize foaming. The vacuum will draw the diluent into the
concentrate vial. If vacuum is lost, use a sterile syringe and needle to remove the sterile
water from the diluent vial and inject it into the Koāte-DVI, directing the stream of fluid
against the wall of the vial.
9. Remove the diluent vial and transfer needle.
10. Agitate vigorously for 10-15 seconds, then swirl continuously until completely
dissolved. Avoid excessive foaming. The reconstituted solution should be clear
to opalescent. Do not use if particulate matter and discoloration is observed.
11. Clean the top of the vial of reconstituted Koāte-DVI with alcohol swab and let surface
dry.
12. Attach the filter needle (from the package) to a sterile syringe. Withdraw the Koāte-DVI
solution into the syringe through the filter needle.
13. Remove the filter needle from the syringe and discard the filter needle into a puncture
proof container. Use Koāte-DVI within 3 hours after reconstitution. Do not refrigerate
after reconstitution.
